Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.
Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL. Uusi-Kerttula H, et al. Among authors: evgin l. Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24. Clin Cancer Res. 2018. PMID: 29798908
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.
Kottke T, Evgin L, Shim KG, Rommelfanger D, Boisgerault N, Zaidi S, Diaz RM, Thompson J, Ilett E, Coffey M, Selby P, Pandha H, Harrington K, Melcher A, Vile R. Kottke T, et al. Among authors: evgin l. Cancer Immunol Res. 2017 Nov;5(11):1029-1045. doi: 10.1158/2326-6066.CIR-17-0175. Epub 2017 Oct 15. Cancer Immunol Res. 2017. PMID: 29038298 Free PMC article.
APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.
Huff AL, Wongthida P, Kottke T, Thompson JM, Driscoll CB, Schuelke M, Shim KG, Harris RS, Molan A, Pulido JS, Selby PJ, Harrington KJ, Melcher A, Evgin L, Vile RG. Huff AL, et al. Among authors: evgin l. Mol Ther Oncolytics. 2018 Aug 29;11:1-13. doi: 10.1016/j.omto.2018.08.003. eCollection 2018 Dec 21. Mol Ther Oncolytics. 2018. PMID: 30294666 Free PMC article.
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.
Evgin L, Huff AL, Kottke T, Thompson J, Molan AM, Driscoll CB, Schuelke M, Shim KG, Wongthida P, Ilett EJ, Smith KK, Harris RS, Coffey M, Pulido JS, Pandha H, Selby PJ, Harrington KJ, Melcher A, Vile RG. Evgin L, et al. Cancer Immunol Res. 2019 May;7(5):828-840. doi: 10.1158/2326-6066.CIR-18-0013. Epub 2019 Apr 2. Cancer Immunol Res. 2019. PMID: 30940643 Free PMC article.
Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors.
Wongthida P, Schuelke MR, Driscoll CB, Kottke T, Thompson JM, Tonne J, Stone C, Huff AL, Wetmore C, Davies JA, Parker AL, Evgin L, Vile RG. Wongthida P, et al. Among authors: evgin l. Neuro Oncol. 2020 Dec 18;22(12):1757-1770. doi: 10.1093/neuonc/noaa126. Neuro Oncol. 2020. PMID: 32459315 Free PMC article.
Oncolytic virus-derived type I interferon restricts CAR T cell therapy.
Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Tonne J, Schuelke M, Ayasoufi K, Driscoll CB, Shim KG, Reynolds P, Monie DD, Johnson AJ, Coffey M, Young SL, Archer G, Sampson J, Pulido J, Perez LS, Vile R. Evgin L, et al. Nat Commun. 2020 Jun 24;11(1):3187. doi: 10.1038/s41467-020-17011-z. Nat Commun. 2020. PMID: 32581235 Free PMC article.
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.
Driscoll CB, Schuelke MR, Kottke T, Thompson JM, Wongthida P, Tonne JM, Huff AL, Miller A, Shim KG, Molan A, Wetmore C, Selby P, Samson A, Harrington K, Pandha H, Melcher A, Pulido JS, Harris R, Evgin L, Vile RG. Driscoll CB, et al. Among authors: evgin l. Nat Commun. 2020 Feb 7;11(1):790. doi: 10.1038/s41467-020-14568-7. Nat Commun. 2020. PMID: 32034147 Free PMC article.
29 results